Janssen in Zug is the Swiss sales and marketing subsidiary of the research-based, global leader in the pharmaceutical industry. The company develops pharmaceutical preparations for pain relief, gynecology, neurology, psychiatry and virology. Janssen has developed over 80 drugs, five of which are included in the WHO list of the most important medications.
Johnson & Johnson and Janssen are deeply engrained in Switzerland. Janssen is the combination of Janssen –founded by Dr. Paul Janssen in Belgium in 1953, and acquired by Johnson & Johnson in 1961 and Cilag, acquired in 1959. Cilag was founded by Dr. Bernhard Joos in Switzerland in 1936. In 1994 Janssen and Cilag merged and since 2010 are operating under the Janssen brand name.
Contact
Janssen-Cilag AG
Gubelstrasse 34
CH-6300 Zug
tel +41 58 231 34 46
Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients,…
Nasri Nahas, CEO of Biopôle in Switzerland, discusses his motivations for joining the biotech, and his mission to re-position the organization as a life sciences ecosystem bringing together academia, business, and…
The Chairman of Ferring’s Group Operating Committee and Senior Vice President Europe-Canada elaborates on how Europe can be the thinking engine for global pharmaceutical trends. Ferring has bundled the…
An expert in the implementation of Swiss federal laws within Switzerland’s constituent cantons, Giovan Maria Zanini discusses the evolution of Swiss pharma regulatory framework and efforts to strengthen and protect…
Switzerland may have a world class healthcare system, but small adjustments are needed to ensure incentives for payer and providers are properly aligned with the patient’s ultimate quality and value…
Advances in delivery technology and manufacturing costs have driven a surge of activity in peptide drug development, says Thomas Früh, CEO of Bachem – the largest and most advanced peptide…
Outsourcing of API synthesis has stabilized in the decade since Rohner Chem entered the pharma sector in earnest, and according to CEO Daniel Pedrett the company has reached a position…
Helsinn is a leader in cancer supportive care, and Vice Chairman and CEO Riccardo Braglia enthusiastically discusses the Group’s entrance into the field of oncology therapeutics and the launch of…
With over 50 years of history in Switzerland, Zambon operates in Canton Ticino one of Zambon’s two major global production centers. Swiss Market Manager Giampiero Roncoroni discusses the unique features…
With 40 years of history in Switzerland, B Braun serves every hospital in the country and operates three distinct production sites. CEO Madeleine Stöckli discusses her strategy for improving productivity…
Sintetica, Switzlerland’s longtime leader in local anesthesia and pain relief with development efforts in neuromodulation, started an ambitious internationalization strategy in 2011. CEO Augusto Mitidieri discusses the company’s expansion progress…
The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons…
Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20…
See our Cookie Privacy Policy Here
